



REVA ANNOUNCES FIRST IMPLANT OF THE FANTOM ENCORE BIORESORBABLE SCAFFOLD IN SWITZERLAND

San Diego, California and Sydney, Australia (Wednesday, 28 March 2018, AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of the Fantom® Encore bioresorbable scaffold (“BRS”) in Switzerland. The procedure was conducted by PD Dr. med Gregor Leibundgut at Medizinische Universitätsklinik, Kantonsspital Baselland in Liestal.

“REVA’s Tyrocore™ polymer makes Fantom Encore the most advanced bioresorbable scaffold with x-ray visibility and the thinnest strut profile in the 2.5 mm diameter size,” said Dr. Leibundgut. “During the procedure, I experienced the flexibility and ease-of-use provided by a thinner strut profile as well as excellent scaffolding. A thinner strut profile, without compromising strength, as well as the excellent visibility of the scaffold are some of the most important improvements over first generation bioresorbable scaffolds.”

Fantom Encore is a novel BRS made from Tyrocore, REVA’s proprietary polymer designed specifically for vascular scaffolds. First generation bioresorbable scaffolds are made from two materials: polylactic acid and a magnesium alloy, which are not x-ray visible, and are limited by their thick strut profiles, approximately 150 microns. Fantom Encore is x-ray visible and offers a thin 95 micron strut profile in the 2.5 mm diameter size, which is more than a 35% reduction relative to first generation scaffolds. These features are associated with improved ease-of-use, vessel healing, and long-term clinical performance.

“Many of the physicians we work with believe that bioresorbable scaffolds are the future of coronary artery disease therapy. With its thin strut profile, x-ray visibility, and ease-of-use, Fantom Encore is delivering that future today,” said Reggie Groves, CEO, REVA Medical. “The first implant of Fantom Encore in Switzerland is an important step in expanding use of our technology and broader commercial adoption.”

About Fantom and Fantom Encore

Fantom and Fantom Encore are sirolimus-eluting bioresorbable scaffolds developed as an alternative to metallic stents for the treatment of coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, and then disappear (or “resorb”) from the body over a period of time. This resorption is intended to allow the return of natural movement and function of the artery. Fantom and Fantom Encore are the only bioresorbable scaffolds made from Tyrocore, REVA’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently radiopaque, making Fantom and Fantom Encore the first and only bioresorbable scaffolds that are visible under fluoroscopy. Fantom and Fantom Encore are designed with thin struts while maintaining strength and with distinct ease-of-use features such as expansion with one continuous inflation.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the U.S. and Europe.

Fantom, Fantom Encore, and Tyrocore are trademarks of REVA Medical, Inc.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on March 7, 2018, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**United States
Investor & Media Enquiries:**
REVA Medical, Inc.
Brandi Roberts
Chief Financial Officer
+1 858-966-3003
Cheryl Liberatore
Director, Communications
+1 858-966-3045
ir@revamedical.com

**Australia
Investor Enquiries:**
Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

**Australia
Media Enquiries:**
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722